Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Non-Current Debt (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 5 years of Non-Current Debt data on record, last reported at $2.2 million in Q2 2025.

  • For Q2 2025, Non-Current Debt fell 87.05% year-over-year to $2.2 million; the TTM value through Jun 2025 reached $2.2 million, down 87.05%, while the annual FY2024 figure was $9.6 million, 60.74% down from the prior year.
  • Non-Current Debt reached $2.2 million in Q2 2025 per RANI's latest filing, down from $5.9 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $29.3 million in Q2 2023 and bottomed at $2.2 million in Q2 2025.
  • Average Non-Current Debt over 4 years is $18.6 million, with a median of $19.0 million recorded in 2024.
  • Peak YoY movement for Non-Current Debt: skyrocketed 99.43% in 2023, then tumbled 87.05% in 2025.
  • A 4-year view of Non-Current Debt shows it stood at $29.1 million in 2022, then fell by 16.0% to $24.5 million in 2023, then tumbled by 60.74% to $9.6 million in 2024, then tumbled by 76.81% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $2.2 million in Q2 2025, $5.9 million in Q1 2025, and $9.6 million in Q4 2024.